Abstract 18P
Background
Lung cancer accounts for 18% of cancer-related deaths globally, due to its high incidence and mortality rates. Radiotherapy is standard of care but radioresistance remains an area of clinical need. Aurora kinase B (AURKB) is a mitotic kinase with links to DNA damage repair (DDR). Given AURKB’s canonical functions in mitotic progression and its interactions with DDR proteins such as p53, Ku70 and H2AX, we hypothesized that inhibition of AURKB via the clinical inhibitor Barasertib (AZD1152) would radiosensitise NSCLC.
Methods
H460 cells were used as a NSCLC in vitro model. Survival fraction was assessed by clonogenic assay. Mitotic phenotypes and DDR markers were analysed by immunofluorescence. Phospho-Mass spectrometry (MS) was carried out on a Thermo Orbitrap LC-MS with TMT tagging and phospho-peptide enrichment using TiO2 beads. In vivo experiments were performed using a H460 xenograft model in Balb/c nude mice.
Results
We found that AURKB inhibition by Barasertib and siRNA radiosensitises NSCLC in vitro. We assessed changes in peptide phosphorylation using global phospho-MS. Comparing IR and IR-Barasertib conditions, significant changes in phospho-peptides representing proteins involved in cell cycle regulation, DDR and survival signalling were observed. Consistent with this we found significant changes in the mitotic response of cells to IR when co-treated with Barasertib. There were greater mitotic defects in Barasertib treated cells including centrosomal amplification and chromosomal segregation defects. Live cell microscopy indicated that Barasertib treatment leads to greater mitotic duration, increased occurrences of slippage, abscission regression and mitotic death compared with IR alone. Interestingly in contrast to indications of the phospho-MS data no change in the DNA repair dynamics of interphase cells was found. Trials are underway to test the efficacy of the IR-Barasertib combination on tumour growth in vivo.
Conclusions
In conclusion, Barasertib radiosensitises NSCLC cells by disrupting mitotic fate. This holds promise for clinical application in highly proliferative tumours.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
MRC DiMen DTP Weston Park Cancer Charity.
Disclosure
C.E. Eyers: Non-Financial Interests, Institutional, Advisory Board, Panel member: BBSRC. All other authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract